Literature DB >> 21674176

Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register.

S Gudbjörnsdottir1, B Eliasson, K Eeg-Olofsson, B Zethelius, J Cederholm.   

Abstract

AIMS/HYPOTHESIS: The study aimed to assess the relative importance of the control of HbA(1c) and total cholesterol/HDL-cholesterol ratio (TC/HDL) on risk of cardiovascular disease (CVD).
METHODS: In 22,135 participants with type 2 diabetes (age 30-75 years, 15% with previous CVD) followed for 5 years, baseline and annually updated mean HbA(1c) and TC/HDL were analysed and also categorised in combinations of quartiles. Outcomes were fatal/non-fatal CHD, stroke, CVD and total mortality.
RESULTS: In all participants, HRs per 1 SD increase in updated mean HbA(1c) or TC/HDL using Cox regression analysis were 1.13 (95% CI 1.07, 1.19) and 1.31 (1.25, 1.37) for CHD, 1.15 (1.06, 1.24) and 1.25 (1.17, 1.34) for stroke, 1.13 (1.08, 1.18) and 1.29 (1.24, 1.34) for CVD (all p < 0.001), and 1.07 (1.02, 1-13; p = 0.01) and 1.18 (1.12, 1.24; p < 0.001) for total mortality, respectively, adjusted for clinical characteristics and traditional risk factors. The p value for the interaction between HbA(1c) and TC/HDL was 0.02 for CHD, 0.6 for stroke and 0.1 for CVD. Adjusted mean 5-year event rates in a Cox model, in combinations of quartiles of updated mean TC/HDL and HbA(1c) (lowest <3.1 mmol/l and 5.0-6.4% [31-46 mmol/mol]; <3.1 mmol/l and ≥7.8% [≥62 mmol/mol]; ≥4.6 mmol/l and 5.0-6.4% 31-46 mmol/mol; and highest ≥4.6 mmol/l and ≥7.8% [≥62 mmol/mol]), were 4.8%, 7.0%, 9.1% and 14.5% for CHD, and 7.1%, 9.9%, 12.8% and 19.4% for CVD, respectively. Adjusted HRs for highest vs lowest combinations were 2.24 (1.58-3.18) for CHD and 2.43 (1.79-3.29) for CVD (p < 0.001). CONCLUSIONS/
INTERPRETATION: Hyperglycaemia and hyperlipidaemia were less than additive for CHD and additive for other endpoints, with the lowest risk at lowest combination levels and a considerable increase in absolute risk at high combination levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674176     DOI: 10.1007/s00125-011-2218-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  35 in total

1.  Intensified glucose lowering in type 2 diabetes: time for a bolder reappraisal.

Authors:  L Czupryniak; E Szymańska-Garbacz; M Pawłowski; M Saryusz-Wolska; J Loba
Journal:  Diabetologia       Date:  2010-12-15       Impact factor: 10.122

2.  Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register.

Authors:  Peter M Nilsson; Jan Cederholm; Katarina Eeg-Olofsson; Björn Eliasson; Björn Zethelius; Robert Fagard; Soffia Gudbjörnsdóttir
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2009-08

3.  Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers.

Authors:  J Merlo; U Lindblad; H Pessah-Rasmussen; B Hedblad; J Rastam; S O Isacsson; L Janzon; L Råstam
Journal:  Eur J Epidemiol       Date:  2000-03       Impact factor: 8.082

4.  The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care.

Authors:  Soffia Gudbjörnsdottir; Jan Cederholm; Peter M Nilsson; Björn Eliasson
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

5.  Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.

Authors:  Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

6.  Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR).

Authors:  Katarina Eeg-Olofsson; Jan Cederholm; Peter M Nilsson; Björn Zethelius; Ann-Marie Svensson; Soffia Gudbjörnsdóttir; Björn Eliasson
Journal:  Diabetes Care       Date:  2010-04-27       Impact factor: 19.112

7.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

8.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

9.  Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes.

Authors:  S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  Stroke       Date:  1996-01       Impact factor: 7.914

10.  Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).

Authors:  Jan Cederholm; Björn Zethelius; Peter M Nilsson; Katarina Eeg-Olofsson; Björn Eliasson; Soffia Gudbjörnsdottir
Journal:  Diabetes Res Clin Pract       Date:  2009-08-12       Impact factor: 5.602

View more
  10 in total

1.  Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.

Authors:  S Zoungas; J Chalmers; T Ninomiya; Q Li; M E Cooper; S Colagiuri; G Fulcher; B E de Galan; S Harrap; P Hamet; S Heller; S MacMahon; M Marre; N Poulter; F Travert; A Patel; B Neal; M Woodward
Journal:  Diabetologia       Date:  2011-12-21       Impact factor: 10.122

2.  Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR).

Authors:  Björn Zethelius; Soffia Gudbjörnsdottir; Björn Eliasson; Katarina Eeg-Olofsson; Ann-Marie Svensson; Jan Cederholm
Journal:  Diabetologia       Date:  2015-06-19       Impact factor: 10.122

3.  Cyclooxygenase 2, toll-like receptor 4 and interleukin 1β mRNA expression in atherosclerotic plaques of type 2 diabetic patients.

Authors:  Alessandro Baldan; Silvia Ferronato; Silvia Olivato; Giovanni Malerba; Alberto Scuro; Gian Franco Veraldi; Matteo Gelati; Sergio Ferrari; Sara Mariotto; Pier Franco Pignatti; Sara Mazzucco; Macarena Gomez-Lira
Journal:  Inflamm Res       Date:  2014-08-06       Impact factor: 4.575

Review 4.  Registry-based randomised clinical trials: a remedy for evidence-based diabetes care?

Authors:  Jan W Eriksson; Björn Eliasson; Louise Bennet; Johan Sundström
Journal:  Diabetologia       Date:  2022-07-29       Impact factor: 10.460

5.  Total/high density lipoprotein cholesterol and cardiovascular disease (re)hospitalization nadir in type 2 diabetes.

Authors:  Dahai Yu; Yamei Cai; Rui Qin; Jonathan Graffy; Daniel Holman; Zhanzheng Zhao; David Simmons
Journal:  J Lipid Res       Date:  2018-06-29       Impact factor: 5.922

6.  Metabolic predictors of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age.

Authors:  Toshio Hayashi; Atsushi Araki; Seinosuke Kawashima; Hirohito Sone; Hiroshi Watanabe; Takashi Ohrui; Koutaro Yokote; Minoru Takemoto; Kiyoshi Kubota; Mitsuhiko Noda; Hiroshi Noto; Koichiro Ina; Hideki Nomura
Journal:  Cardiovasc Diabetol       Date:  2013-01-09       Impact factor: 9.951

7.  Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study.

Authors:  Gregory A Nichols; Sandra Joshua-Gotlib; Shreekant Parasuraman
Journal:  J Gen Intern Med       Date:  2013-01-24       Impact factor: 5.128

8.  Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register.

Authors:  Nils Ekström; Jan Cederholm; Björn Zethelius; Björn Eliasson; Eva Fhärm; Olov Rolandsson; Mervete Miftaraj; Ann-Marie Svensson; Soffia Gudbjörnsdottir
Journal:  BMJ Open       Date:  2013-04-20       Impact factor: 2.692

9.  Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis.

Authors:  John Peter Mitsios; Elif Ilhan Ekinci; Gregory Peter Mitsios; Leonid Churilov; Vincent Thijs
Journal:  J Am Heart Assoc       Date:  2018-05-17       Impact factor: 5.501

10.  Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.

Authors:  Silvio E Inzucchi; Kamlesh Khunti; David H Fitchett; Christoph Wanner; Michaela Mattheus; Jyothis T George; Anne Pernille Ofstad; Bernard Zinman
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.